Substitute PTO/SB/08A-B (08-03) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

Sheet

Substitute for form 1449A/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

1

Complete if Known				
Application Number	10/667,299			
Filing Date	September 18, 2003			
First Named Inventor	ZANETTI, Maurizio			
Art Unit	1614			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	A-58624-2/RFT/RMK (466673-33)			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear
	A1				

1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
0	B1	EP 0 537 430 A1	04-21-1993	Rütgerswerke AG		
	B2	EP 0 540 945 A1	05-12-1993	Torf Establishment		
	-Вз	WO 90/04412-A1	05-03-1990	Regents of the University of Minnesota		
£	B4	WO 92/16216 A1	10-01-1992	Torf Establishment		
Section in the two car and on	B5	WO 94/18957-A1 CONTROL OF CONT	09-01-1994	Levi, Ina		

Lined Through Hems not supplied

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
	C1	FLAIG, W., "Humic substances and associated small molecules from peats in balneology," Sci. Total Environ. 117-118:561-567 (1992).	
	C2	HILS, J.; et al.; "Inhibition of several strains of influenza virus type A and B by phenolic polymers," Biomed. Biochim. Acta 45(9):1173-1179 (1986).	
gantalise signs	C3	KLOECKING, R., et al., "Antiviral properties of humic acids," Chem. Abstracts, CAS Accession No. 77:57054q (1972).	Π
***	C4	LOYA, S., et al., "Hexaprenold Hydroquinones, Novel Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Syndrome," J. Nat. Prods. 56(12):2120-2125 (Dec. 1993).	
	-G5	-RIEDE, U., et al., "Humates as antiviral agents," Chem. Abstracts, CAS Accession No. 118:247623n (1993).	
	C6	SCHNEIDER, J., et al., "HIV-Virostatic Effects of Humic Acids," Off. J. Eur. Soc. Pathol., 190(3):245 (1994).	Γ
N	C7	SCHNEIDER, J., et al., "Inhibition of HIV-1 Infection by Synthetic Huminates," VIII Intl. Conf. AIDS/III STD World Cong., Abstract No. PuA 6152, p. 36, Amsterdam: NL (Jul. 19-24, 1992).	
Carry, gar yours	C8	THIEL, K.D., "Comparison of the <i>in vitro</i> effect of ammonium humate and of enzymically oxidized chlorogenic and caffeic acids against type 1 and type 2 human herpes virus," <i>Chem. Abstracts</i> , CAS Abstract No. 94:150166p (1981).	
·	C9	THIEL, K.D., et al., "In-vitro Studies of the Antiviral Activity of Ammonium Humate Against Herpes simplex Virus Type 1 and Type 2," Zbl. Bakt. Hyg., I. Abt. Orig. A 239:304-321 (1977).	
entroportion of	C10	WAGNER, H., "Topical agent for treatment of vesicular rash caused by herpes virus," Chem. Abstracts, CAS Accession No. 113:65270j (1990).	

Examiner Signature	(105)	Date Considered	8/18/04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.

If if possible.

Applicant is to place a check mark here if English Language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not